PTT-010

PTT-010 is an early-stage drug candidate being developed by Pyrotech Therapeutics for the treatment of Hepatitis B Virus (HBV) infection. Pyrotech Therapeutics focuses on the discovery of small molecules that modulate the pyroptosis pathway, a form of programmed cell death associated with intense inflammatory responses. PTT-010 is categorized within the company's autoimmune and anti-inflammatory portfolio, suggesting its therapeutic approach involves modulating the immune environment or inflammatory signaling associated with chronic HBV infection. As of early 2024, the program is in the early discovery phase, and its specific molecular target has not been publicly disclosed.